Seeking Alpha article, page-67

First 67 Last

Share
Profile

Follow
igorot72

756 Posts.

73

01/12/18

08:30

Post #: 36714245
Share

Originally posted by Cadel ↑

I totally agree. They should concentrate on what they have and get it done well. I imagine AT and the gang think the same thing but know that good resources will be worth a lot more future and if the right opportunity comes up I’m sure they would at least look at it.

I think if an opportunity comes it will be in Canada. Avalon advanced materials on the Toronto stock exchange would have to be worth a look it’s MC has come down a lot and they keep going to the market for cash, it would have to dry up shortly. They have done lots of testing of the product etc. and I think they have their studies done from memory. Another could be Sayona SYA. I originally thought they would get funding through AJMs connections but since AJM seems to be having a hard time maybe GXY could be the knight in shinning armour.

I have always thought the converter will end up in Canada so it makes sense to have an extra resource or two over there. All just depends on how long they want to play this out. If they want GXY to hit its peak within the next decade stick with the 3. If they want to dominate for decades to come play the long game and add resources while they are cheap.

Expand

"add resources while they are cheap." it's very true. GXY is right now seems to be in a 'position of strength'. opportunities everywhere to grow the company. adding a new resource while they are cheap is for me a good insurance - as long as they do due diligence and resource is there. in future mine it or sell it..

GXY Price at posting: $2.70 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WA1

HotCopper users bullish on WA1 Resources' latest niobium testwork results

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals